Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 171

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 171
---
 the Opella discontinued operation was €274 million lower in 2024 than in 2023. This year-on-year change reflects in particular the acceleration in 2024 of the transformational project to create the standalone Opella entity; transaction costs incurred in 2024 in respect of the proposed Opella transfer; and changes in gains from asset divestments within the Opella scope between the two periods. In addition, net income from the Opella discontinued operation for the year ended December 31, 2024 includes a net tax expense of €122 million relating to the tax cost of the legal restructuring of the Opella scope. For the year ended December 31, 2023, net income from the Opella discontinued operation includes a €365 million deferred tax liability recognized in respect of investments in consolidated entities in light of the proposed separation of the Opella business. 18/ Net income attributable to non-controlling interests Net income attributable to non-controlling interests was € 58 million in 2024 , versus € 36 million in 2023 . 19/ Net income attributable to equity holders of Sanofi Net income attributable to equity holders of Sanofi amounted to € 5,560 million in 2024 , compared with € 5,400 million in 2023 . Basic earnings per share for 2024 was € 4.44 versus € 4.31 for 2023 , based on an average number of shares outstanding of 1,251.4 million in 2024 and 1,251.7 million in 2023 . Diluted earnings per share for 2024 was € 4.43 versus € 4.30 for 2023 , based on an average number of shares after dilution of 1,256.1 million in 2024 and 1,256.4 million in 2023 . A.2.3. Segment results Our business operating income, as defined in Note D.35. (“Segment information”) to our consolidated financial statements included at Item 18. of this annual report, was € 11,343 million in 2024 , compared with € 11,178 million in 2023 (a increase of 1.5 %). It represented 27.6 % of our net sales in 2024, compared with 29.6 % in 2023 . Our business operating income (non-IFRS) is reconciled with our operating income (IFRS) in N ote "D.